Molecular Cancer Therapeutics CTRC-AACR San Antonio Breast Cancer Symposium Targeting the PI3-Kinase Pathway in Cancer
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wahl, M. L.
Right arrow Articles by Owen, C. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wahl, M. L.
Right arrow Articles by Owen, C. S.
Vol. 1, 617-628, June 2002     Molecular Cancer Therapeutics
© 2002 American Association for Cancer Research

Regulation of Intracellular pH in Human Melanoma: Potential Therapeutic Implications1

Miriam L. Wahl2, Judith A. Owen, Randy Burd, Robin A. Herlands, Suzanne S. Nogami, Ulrich Rodeck, David Berd, Dennis B. Leeper and Charles S. Owen

Department of Biochemistry and Molecular Pharmacology [M. L. W., C. S. O.], and Department of Biology [J. A. O., R. A. H., S. S. N.], Haverford College, Haverford, Pennsylvania 19041, and Departments of Radiation Oncology [R. B., D. B. L.], Dermatology and Cutaneous Biology [U. R.], and Medicine [D. B.], and Kimmel Cancer Center [M. L. W., D. B. L.], Thomas Jefferson University, Philadelphia, Pennsylvania 19107

Melanoma cells in vivo maintain intracellular pH (pHi) in a viable range despite an extracellular tumor pH (pHe) that is typically below 7.0. In general, three families of transporters are capable of removing metabolic protons, but the specific transporters responsible for the maintenance of pHi at low pHe in melanomas have not been identified. Although the transporters exist in most cells, an inhibitor would be predicted to have selectivity for cells located in an acidic tumor bed because cells in that environment would be expected to have transporters chronically activated. In this report, the levels and extent of expression of the Na+/H+ exchanger (NHE-1) and two of the H+-linked monocarboxylate transporters (MCTs) were evaluated in three melanoma cell lines. The effects of inhibitors of each transporter were tested at an extracellular pH (pHe) of 7.3, 6.7, or 6.5 in melanoma cells that were grown at pHe 7.3 or 6.7. The activity of MCT isoform 1 (MCT-1) was up-regulated in three melanoma cell lines at low pHe, but that of NHE-1 was not. Furthermore, NHE-1 activity was lower in the melanomas than in other normal and malignant cell lines that were tested. Reverse transcription-PCR using primers specific for MCT-1, MCT-4, and NHE-1 showed that expression of none of these transporters was reproducibly up-regulated at the level of transcription when cells were grown at pHe 6.7 instead of pHe 7.3. Ex vivo experiments using DB-1 human melanoma xenografts grown in severe combined immunodeficient mice found that MCT-1 and not NHE-1 was a major determinant of DB-1 tumor cell pHi. Taken together, the data indicate that MCTs are major determinants of pH regulation in melanoma. In contrast, keratinocytes and melanocytes under low pHe conditions relied on NHE-1. Inhibitors of MCTs thus have great potential to improve the effectiveness of chemotherapeutic drugs that work best at low pHi, such as alkylating agents and platinum-containing compounds, and they should be selective for cells in an acidic tumor bed. In most tissues, it is proposed that the NHE-1 could compensate for an inhibited MCT to prevent acidification, but in melanoma cells this did not occur. Therefore, MCT inhibitors may be particularly effective against malignant melanoma.




This article has been cited by other articles:


Home page
Vet PatholHome page
Y. Shimoyama, Y. Akihara, D. Kirat, H. Iwano, K. Hirayama, Y. Kagawa, T. Ohmachi, K. Matsuda, M. Okamoto, T. Kadosawa, et al.
Expression of Monocarboxylate Transporter 1 in Oral and Ocular Canine Melanocytic Tumors
Vet. Pathol., July 1, 2007; 44(4): 449 - 457.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
J. Fang, Q. J. Quinones, T. L. Holman, M. J. Morowitz, Q. Wang, H. Zhao, F. Sivo, J. M. Maris, and M. L. Wahl
The H+-Linked Monocarboxylate Transporter (MCT1/SLC16A1): A Potential Therapeutic Target for High-Risk Neuroblastoma
Mol. Pharmacol., December 1, 2006; 70(6): 2108 - 2115.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
C. P. Landowski, B. S. Vig, X. Song, and G. L. Amidon
Targeted delivery to PEPT1-overexpressing cells: Acidic, basic, and secondary floxuridine amino acid ester prodrugs
Mol. Cancer Ther., April 1, 2005; 4(4): 659 - 667.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
F. Turturro, E. Friday, R. Fowler, D. Surie, and T. Welbourne
Troglitazone Acts on Cellular pH and DNA Synthesis through a Peroxisome Proliferator-Activated Receptor {gamma}-Independent Mechanism in Breast Cancer-Derived Cell Lines
Clin. Cancer Res., October 15, 2004; 10(20): 7022 - 7030.
[Abstract] [Full Text] [PDF]


Home page
Recent Prog Horm ResHome page
M. L. Wahl, T. L. Moser, and S. V. Pizzo
Angiostatin and Anti-angiogenic Therapy in Human Disease
Recent Prog. Horm. Res., January 1, 2004; 59(1): 73 - 104.
[Abstract] [Full Text]


Home page
Molecular Cancer TherapeuticsHome page
R. A. Coss, C. W. Storck, C. Daskalakis, D. Berd, and M. L. Wahl
Intracellular Acidification Abrogates the Heat Shock Response and Compromises Survival of Human Melanoma Cells
Mol. Cancer Ther., April 1, 2003; 2(4): 383 - 388.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2002 by the American Association for Cancer Research.